PuSH - Publication Server of Helmholtz Zentrum München: Omics: Potential role in early phase drug development.

Information

Clues to quality of journals

Open Access Policy of Helmholtz Association 2016

CC Licencences

Publication Metrics

Navigation

Home

Deutsch

EVA: Electronic Publishing

New EVA Application

Research

Advanced Search

Browse by ...

... HMGU-Authors/Consortia

... Organizational Structure

... Journal

... Publication Type

... Research Data

... Arbeitsgruppen

... Publication Year

Publication overview

Statistics

Statistics (last 5 years)

OA Publications

Publish

Submit Publication

Import publication from...

...EVA

Report missing publication

Highlights

Support & Contact

Contact persons

Help

Data protection

Helmholtz Open Science

JANE Journal Estimator

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Grallert, H. ; Marzi, C. ; Hauck, S.M. ; Gieger, C.

Omics: Potential role in early phase drug development.

In: Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. 2019. 309-347

DOI

Abstract
Metrics
Extra information

Background The development of high-throughput omics technologies has nourished the hope to improve our understanding and treatment of the pathophysiology of globally increasing diseases such as type 2 diabetes, obesity, and nonalcoholic fatty liver disease/ nonalcoholic steatohepatitis (NAFLD/ NASH). These technologies provide innovative tools that have the potential to truly revolutionize patient care. Key Methods (a) Genomics, Epigenomics, Transcriptomics Technologies continue to propel the omics fields forward. However, translating research discovery into routine clinical applications use is a complex process not only from scientific prospective but also from ethical, political, and logistic points of view. Particularly the implementation of omics-based tests requires changes in fundamental processes of regulation, reimbursement, and clinical practice. Altogether, developments in the field of omics technologies hold great promise to optimize patient care and improve outcomes and eventually lead to new tests and treatments that are well integrated in routine medical care of people with obesity, type 2 diabetes and NAFLD/ NASH.

Altmetric